Cogstate : Announces Formation of Scientific Advisory Board
June 14, 2022 at 08:13 pm IST
Share
Leadingclinical and scientific experts in neurodegenerative diseases and pharmaceutical research will provide guidance to progress Cogstate's strategy
Cogstate (ASX.CGS), a leading neuroscience technology company, today announced the formation of a Scientific Advisory Board (SAB), comprising clinical and scientific experts in cognitive assessment and drug development. The SAB will work closely with the Cogstate scientific leadership team to support the advancement of the company's strategy, innovation roadmaps, and research & development initiatives.
The SAB will be chaired by Eric Siemers, MD, whose clinical trial experience spans 25 years including serving as the Distinguished Medical Fellow for Eli Lilly and Company's Alzheimer's Disease Global Development Team and founding the Indiana University Movement Disorder Clinic. He currently serves as Cogstate's Distinguished Medical Adviser and as the Chief Medical Officer at Acumen Pharmaceuticals.
Additional members of the initial cohort of SAB members include:
Bruce Albala, PhD - Associate Dean of Innovation and Clinical Trials and Professor of Neurology at the University of California Irvine School of Medicine
Adam Brickman, PhD - Professor of Neuropsychology at Columbia University, the Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H. Sergievsky Center
Sharon Cohen, MD FRCPC - Behavioral Neurologist and Medical Director of the Toronto Memory Program
Kate Papp, PhD - Assistant Professor of Neurology at Harvard Medical School and Clinical Neuropsychologist at Brigham and Women's Hospital and Massachusetts General Hospital
Craig Ritchie, MD, PhD - Professor at the University of Edinburgh, Director of Edinburgh Centre for Dementia Prevention, and Director of Brain Health Scotland
Sietske Sikkes, PhD - Associate Professor at the VU University and the Alzheimer Center Amsterdam of the Amsterdam University Medical Center
"We are honored to welcome this group of world-class neuroscience experts and are grateful for the guidance they will provide us as we progress our mission to improve brain health assessment," said Chris Edgar, PhD, Chief Science Officer at Cogstate. "I'm confident their insights will be impactful for informing Cogstate R&D plans and activities, particularly in areas such as Alzheimer's disease and related dementias."
About Cogstate
Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
Back to News
Attachments
Original Link
Original Document
Permalink
Disclaimer
CogState Ltd. published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 14:42:08 UTC.
Cogstate Ltd is a neuroscience technology company. It is engaged in the creation, validation, and commercialization of digital brain health assessments and design and assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Research. The Clinical Trials segment includes adoption of decentralized clinical trial methodologies and scientific publication and marketing of the utility and validity of Cogstate technology. The Healthcare segment includes Cognigram, which allows for regular and standardized testing to assist in the early detection of cognitive decline that could be related to a range of factors including head injury, neurodegenerative disease or side effects following pharmacological treatments. The Research segment includes research studies and academic collaborations across various indications, such as Alzheimerâs disease and Parkinsonâs disease.